aap Implantate AG: above-average turnover and earnings growth in Q3

Berlin, 30 November 2000. aap Implantate AG, one of the leading German companies in the biomedical implant sector, reports above-average turnover and earnings growth in the first nine months of the current financial year. Turnover was up 75% on the year to DM 13.7 million from DM 7.9 million. Operating income increased to DM 2.6 million from minus DM 200 thousands in the review period. DVFA adjusted group profits could almost be tripled and increased to DM 1.5 million during the first nine months of 2000 from 0,5 million in the corresponding period last year.

The aap board attributed this gratifying business trend to markedly higher turnover in the R&D-Services business field and to the expansion of foreign business.

With the further intensification of international sales activities, especially in China, Japan and the U.S., the continuation of development projects in the R&D-Services sector, the acquisition of Coripharm, Mebio and Corimed and the stake in Osartis the management sees substantial growth potential for the future.